GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyperion Therapeutics Inc (FRA:0HY) » Definitions » Price-to-Owner-Earnings

Hyperion Therapeutics (FRA:0HY) Price-to-Owner-Earnings : (As of Jun. 20, 2024)


View and export this data going back to . Start your Free Trial

What is Hyperion Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-20), Hyperion Therapeutics's share price is €39.68. Hyperion Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Hyperion Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


FRA:0HY's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.555
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-20), Hyperion Therapeutics's share price is €39.68. Hyperion Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2015 was €-0.06. Therefore, Hyperion Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-20), Hyperion Therapeutics's share price is €39.68. Hyperion Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.06. Therefore, Hyperion Therapeutics's PE Ratio without NRI for today is At Loss.


Hyperion Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Hyperion Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperion Therapeutics Price-to-Owner-Earnings Chart

Hyperion Therapeutics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14
Price-to-Owner-Earnings
- - - - -

Hyperion Therapeutics Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hyperion Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Hyperion Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyperion Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyperion Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Hyperion Therapeutics's Price-to-Owner-Earnings falls into.



Hyperion Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Hyperion Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=39.68/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyperion Therapeutics  (FRA:0HY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Hyperion Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Hyperion Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyperion Therapeutics (FRA:0HY) Business Description

Traded in Other Exchanges
N/A
Address
Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Hyperion Therapeutics (FRA:0HY) Headlines

No Headlines